FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019926572> ?p ?o ?g. }

• W2019926572 endingPage "544" @default.
• W2019926572 startingPage "537" @default.
• W2019926572 abstract "To analyze disease failure patterns by pretreatment characteristics and treatment groups in a prospective randomized trial.Patients with medically inoperable Stage II, unresectable IIIA and IIIB nonsmall cell lung cancer with KPS > or =70 and weight loss < or =5% were randomized to one of three treatment groups: standard radiation therapy with 60 Gy at 2.0 Gy per day (STD RT), induction chemotherapy with cisplatin 100 mg/m2 days 1 and 29 with vinblastine 5 mg/m2 weekly for 5 weeks followed by 60 Gy at 2.0 Gy per day (CT + RT), or hyperfractionated radiation therapy with 69.6 Gy at 1.2 Gy b.i.d. (HFX RT). Of 490 patients enrolled, 458 were evaluable. Minimum and median periods of observation for this analysis were 4 years and 6 years, respectively.Pretreatment characteristics were equally distributed. Toxicities were previously reported. Median survival rates were 11.4, 13.6, and 12.3 months for STD RT, CT + RT, and HFX RT, respectively (log rank p = 0.05, Wilcoxon p = 0.04). Survivals were 20, 31, and 24% at 2 years, and 4, 11, and 9% at 4 years in the STD RT, CT + RT, and HFX RT groups, respectively. There were no differences in local tumor control rates among the treatments. Patterns of first failure showed less distant metastasis (DM) (other than brain) for CT + RT compared to the RT alone arms (p = 0.04). Within squamous cell carcinoma (SCC), DM (other than brain) rates were 43%, 16%, and 38% in SCC for STD RT, CT + RT, and HFX RT, respectively (p = 0.0015). Patients with peripheral/chest wall lesions were significantly more likely to fail first in the thorax when treated on STD RT compared to CT + RT and HFX RT (p = 0.009). Survival rates were similar among the treatment arms for patients with squamous cell carcinoma. Among patients with nonsquamous cell carcinoma, failure patterns did not differ by treatment group, but survival was significantly better in those who were treated by induction chemotherapy (p = 0.04).Patients with squamous cell carcinoma treated on the CT + RT arm had a significant reduction of first DM other than brain, but there was difference in survival. Survival favored CT + RT in nonsquamous carcinoma despite similar failure patterns. Reasons for improved survival with CT + RT in NSCLC are not yet available." @default.
• W2019926572 created "2016-06-24" @default.
• W2019926572 creator A5011307937 @default.
• W2019926572 creator A5014161715 @default.
• W2019926572 creator A5026088869 @default.
• W2019926572 creator A5030653008 @default.
• W2019926572 creator A5033516554 @default.
• W2019926572 creator A5034765756 @default.
• W2019926572 creator A5042995920 @default.
• W2019926572 creator A5045457153 @default.
• W2019926572 creator A5052461112 @default.
• W2019926572 creator A5060222943 @default.
• W2019926572 creator A5085643126 @default.
• W2019926572 date "1997-10-01" @default.
• W2019926572 modified "2023-10-16" @default.
• W2019926572 title "Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: Failure patterns by cell type in rtog 88-08/ECOG 4588" @default.
• W2019926572 cites W1831241863 @default.
• W2019926572 cites W2014145691 @default.
• W2019926572 cites W2016694541 @default.
• W2019926572 cites W2034840803 @default.
• W2019926572 cites W2061961646 @default.
• W2019926572 cites W2062248834 @default.
• W2019926572 cites W2067096286 @default.
• W2019926572 cites W2078752897 @default.
• W2019926572 cites W2084021660 @default.
• W2019926572 cites W2085675994 @default.
• W2019926572 cites W2132130760 @default.
• W2019926572 cites W2138310931 @default.
• W2019926572 cites W2138945505 @default.
• W2019926572 cites W2143594378 @default.
• W2019926572 cites W2155053061 @default.
• W2019926572 cites W2312703485 @default.
• W2019926572 cites W2317448174 @default.
• W2019926572 cites W4249492944 @default.
• W2019926572 cites W4293241248 @default.
• W2019926572 doi "https://doi.org/10.1016/s0360-3016(97)00365-9" @default.
• W2019926572 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9336129" @default.
• W2019926572 hasPublicationYear "1997" @default.
• W2019926572 type Work @default.
• W2019926572 sameAs 2019926572 @default.
• W2019926572 citedByCount "130" @default.
• W2019926572 countsByYear W20199265722012 @default.
• W2019926572 countsByYear W20199265722013 @default.
• W2019926572 countsByYear W20199265722014 @default.
• W2019926572 countsByYear W20199265722015 @default.
• W2019926572 countsByYear W20199265722016 @default.
• W2019926572 countsByYear W20199265722017 @default.
• W2019926572 countsByYear W20199265722018 @default.
• W2019926572 countsByYear W20199265722019 @default.
• W2019926572 countsByYear W20199265722020 @default.
• W2019926572 countsByYear W20199265722022 @default.
• W2019926572 crossrefType "journal-article" @default.
• W2019926572 hasAuthorship W2019926572A5011307937 @default.
• W2019926572 hasAuthorship W2019926572A5014161715 @default.
• W2019926572 hasAuthorship W2019926572A5026088869 @default.
• W2019926572 hasAuthorship W2019926572A5030653008 @default.
• W2019926572 hasAuthorship W2019926572A5033516554 @default.
• W2019926572 hasAuthorship W2019926572A5034765756 @default.
• W2019926572 hasAuthorship W2019926572A5042995920 @default.
• W2019926572 hasAuthorship W2019926572A5045457153 @default.
• W2019926572 hasAuthorship W2019926572A5052461112 @default.
• W2019926572 hasAuthorship W2019926572A5060222943 @default.
• W2019926572 hasAuthorship W2019926572A5085643126 @default.
• W2019926572 hasConcept C126322002 @default.
• W2019926572 hasConcept C126894567 @default.
• W2019926572 hasConcept C143998085 @default.
• W2019926572 hasConcept C2776256026 @default.
• W2019926572 hasConcept C2776694085 @default.
• W2019926572 hasConcept C2777132456 @default.
• W2019926572 hasConcept C2778239845 @default.
• W2019926572 hasConcept C509974204 @default.
• W2019926572 hasConcept C71924100 @default.
• W2019926572 hasConcept C90924648 @default.
• W2019926572 hasConceptScore W2019926572C126322002 @default.
• W2019926572 hasConceptScore W2019926572C126894567 @default.
• W2019926572 hasConceptScore W2019926572C143998085 @default.
• W2019926572 hasConceptScore W2019926572C2776256026 @default.
• W2019926572 hasConceptScore W2019926572C2776694085 @default.
• W2019926572 hasConceptScore W2019926572C2777132456 @default.
• W2019926572 hasConceptScore W2019926572C2778239845 @default.
• W2019926572 hasConceptScore W2019926572C509974204 @default.
• W2019926572 hasConceptScore W2019926572C71924100 @default.
• W2019926572 hasConceptScore W2019926572C90924648 @default.
• W2019926572 hasIssue "3" @default.
• W2019926572 hasLocation W20199265721 @default.
• W2019926572 hasLocation W20199265722 @default.
• W2019926572 hasOpenAccess W2019926572 @default.
• W2019926572 hasPrimaryLocation W20199265721 @default.
• W2019926572 hasRelatedWork W1965964706 @default.
• W2019926572 hasRelatedWork W2089609493 @default.
• W2019926572 hasRelatedWork W2138235550 @default.
• W2019926572 hasRelatedWork W2347438058 @default.
• W2019926572 hasRelatedWork W2349204430 @default.
• W2019926572 hasRelatedWork W2353276349 @default.
• W2019926572 hasRelatedWork W2387970634 @default.
• W2019926572 hasRelatedWork W2417555288 @default.
• W2019926572 hasRelatedWork W243427647 @default.
• W2019926572 hasRelatedWork W3211657369 @default.

• next